AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15755229
Drug: Diet treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet treatment
Trial: 9221965
Drug: Clozapine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine (150 mg/day for 31 days)
Trial: 2880663
Drug: Visacor (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visacor (200 mg once daily)
Trial: 19338146
Drug: Shenfu Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenfu Injection (SFI)
Trial: 21346105
Drug: Multi-micronutrient supplementation
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-micronutrient supplementation (daily biscuit)
Trial: 19234585
Drug: Alpha-linolenic acid
RxNorm normalized name: Alpha-linolenic Acid
DrugBank: alpha-Linolenic acid (DB00132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-linolenic acid (ALA) supplementation in flax oil (14 g/day)
Trial: 24490806
Drug: Allegra® tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allegra® tablets (phenylalanine-containing ODT)
Trial: 7962890
Drug: Group cognitive-behavioral
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive-behavioral treatment 1
Trial: 7962890
Drug: Group cognitive-behavioral
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive-behavioral treatment 2
Trial: 23553618
Drug: High hardaliye
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High hardaliye (HH) - 500 mL per day
Trial: 23553618
Drug: Low hardaliye
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low hardaliye (LH) - 250 mL per day
Trial: 18779777
Drug: Adjunctive risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adjunctive risperidone therapy
Trial: 3080511
Drug: Astemizole (load),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole (load), 30 mg once daily for 1 week and then 10 mg once daily for 1 week
Trial: 3080511
Drug: Hydroxyzine, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine, 50 mg once daily for 2 weeks
Trial: 3080511
Drug: Terfenadine, 60
RxNorm normalized name: Terfenadine, 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine, 60 mg twice daily for 2 weeks
Trial: 3080511
Drug: Astemizole (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole (no load), 10 mg once daily for 2 weeks
Trial: 24843499
Drug: Liraglutide 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 0.9 mg/day
Trial: 24573588
Drug: Subatmospheric pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subatmospheric pressure therapy (SPT)
Trial: 9025711
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) 3 IU/m2 per day for 14 days
Trial: 9025711
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) 6 IU/m2 per day for 14 days
Trial: 1603479
Drug: High-dose oxytocin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oxytocin (6-mU/minute dosage increments)
Trial: 31025209
Drug: Pulsed dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed dye laser (PDL) and fractional ablative CO2 laser (FACL) treatment (three sessions at 1-month intervals)
Trial: 31025209
Drug: Standard moisturizers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard moisturizers and silicone gels (control treatment)
Trial: 22612620
Drug: Lansoprazole (LPZ)
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole (LPZ) intravenous infusion at doses of 15 mg, 30 mg, and 60 mg
Trial: 17999638
Drug: Vitamins C+E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamins C+E (1 g/day vitamin C plus 400 IU/day vitamin E)
Trial: 10091618
Drug: Apomorphine (subcutaneously,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine (subcutaneously, previously determined dose)
Trial: 2026847
Drug: Pirenzepine (M1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (M1 antagonist)
Trial: 2026847
Drug: 4-DAMP (M3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-DAMP (M3 antagonist)
Trial: 2026847
Drug: AFDX-116 (M2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AFDX-116 (M2 antagonist)
Trial: 2026847
Drug: Antihistamines (pretreatment)
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamines (pretreatment)
Trial: 30092143
Drug: H56:IC31 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H56:IC31 vaccine (two or three vaccinations at different concentrations)
Trial: 30092143
Drug: H56:IC31 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H56:IC31 vaccine (various doses)
Trial: 27481884
Drug: 0.9% sodium
RxNorm normalized name: LMD with 0.9% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride saline solution
Trial: 25301251
Drug: Daily self-weighing
RxNorm normalized name: DAILY SELF DISCOVERY SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily self-weighing intervention with a set of weighing scales
Trial: 7557571
Drug: Fine bran
RxNorm normalized name: bran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fine bran (15 g)
Trial: 2162633
Drug: ANH group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANH group (7.5 ml/kg body weight within 30 min during substitution with 6% HES 200/0.5)
Trial: 31267973
Drug: Neoadjuvant systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant systemic therapy
Trial: 27458066
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (anti-infection, reducing sputum, and support therapy)
Trial: 25467927
Drug: Oral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral therapy (lomustine, cyclophosphamide, etoposide)
Trial: 25467927
Drug: Intravenous therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous therapy (cyclophosphamide, doxorubicin, vincristine - CAV)
Trial: 11586091
Drug: Pulsed paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pulsed paclitaxel at 15 mg/m2
Trial: 11586091
Drug: Pulsed paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pulsed paclitaxel at 20 mg/m2
Trial: 11586091
Drug: Pulsed paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pulsed paclitaxel at 25 mg/m2
Trial: 11586091
Drug: Pulsed low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pulsed low-dose paclitaxel and radiation
Trial: 10211011
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg kg‐1 ketoprofen i.v.
Trial: 10211011
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg kg‐1 ketoprofen i.v.
Trial: 10211011
Drug: 3.0 mg
RxNorm normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 mg kg‐1 ketoprofen i.v.
Trial: 3411660
Drug: Bacillus Calmette-Guerin
RxNorm normalized name: BACILLUS CALMETTE-GUERIN VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus Calmette-Guerin therapy
Trial: 11340683
Drug: Once-daily tobramycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily tobramycin (Mono)
Trial: 11340683
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy with tobramycin/ceftazidime (Conv)
Trial: 9448231
Drug: Nebulized flunisolide
RxNorm normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized flunisolide nasal spray (250 microg, 1 ml, administered three times daily)
Trial: 7960012
Drug: Ouabain standard
RxNorm normalized name: ouabain
DrugBank: Ouabain (DB01092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ouabain standard or bolus intravenous injections of ouabain
Trial: 3109265
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (inhalation of air)
Trial: 23214246
Drug: Zoledronic acid,
RxNorm normalized name: Zoledronic Acid, Anhydrous
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid, administered by slow intravenous drip at 4 mg in 100 ml of 0.9% sodium chloride
Trial: 16081477
Drug: RhEPO (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RhEPO (150 IU kg(‐1) weekly subcutaneous injection; n = 8)
Trial: 16081477
Drug: Control (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (10 ml sterile saline weekly subcutaneous injection; n = 7)
Trial: 26822516
Drug: DHA-enriched meals
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-enriched meals (1720 mg per day for 12 months)
Trial: 23112272
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (doses > 50 U)
Trial: 23112272
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (doses ≤ 50 U)
Trial: 19761837
Drug: 7.5 microg
RxNorm normalized name: Levonorgestrel 37.5 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 microg H5N1 influenza vaccine without adjuvant
Trial: 7989932
Drug: Chemotherapy or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy or autologous transplantation (Control)
Trial: 2659151
Drug: Atenolol 5
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 5 mg intravenously followed by 50 mg orally for six days
Trial: 30622224
Drug: Rapid sequential
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid sequential injection of fentanyl followed by slow injection of hyperbaric bupivacaine
Trial: 23883922
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m² every 21 days or 35 mg/m² on days 1, 8, and 15 every 28 days
Trial: 9014909
Drug: Killed whole‐cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Killed whole‐cell cholera vaccine (two doses per person)
Trial: 8200247
Drug: Placebo (intramuscularly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intramuscularly monthly for three months)
Trial: 18764913
Drug: Intranasal oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal oxygen therapy
Trial: 15231966
Drug: Atomoxetine (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (1.3 mg/kg once daily)
Trial: 10195359
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (MFNS) 200 microg given once daily for 2 weeks
Trial: 8995922
Drug: Evidence-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based treatment approaches
Trial: 307358
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (propranolol therapy)
Trial: 29734923
Drug: Tutor-administered group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tutor-administered group (TAG)
Trial: 31058772
Drug: Enhanced Protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Protein Diet (EPD) with protein‐energy ratio 4 g/100 calories
Trial: 25476156
Drug: 33% reduced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 33% reduced dose radiography
Trial: 15271701
Drug: Ondansetron (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (0.1 mg/kg IV every 6 h)
Trial: 9228472
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B 0.6 mg/kg/day (cumulative dose 8 mg/kg)
Trial: 7962885
Drug: Cue Exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cue Exposure (CE) treatment with 400 min exposure to the sight and smell of preferred drinks over 10 days
Trial: 20626325
Drug: N-acetylcysteine (NAC;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC; 600 mg/day) with cisplatin
Trial: 8871794
Drug: Individual behavioural-cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual behavioural-cognitive therapy
Trial: 6655704
Drug: Marital therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marital therapy
Trial: 1627968
Drug: Buspirone (20-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (20-100 mg/day for 4 weeks)
Trial: 12108557
Drug: Case managers'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Case managers' verbal reminders about consequences of nonadherence to treatment
Trial: 8578808
Drug: RRV‐S1 (serotype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRV‐S1 (serotype 1 monovalent rotavirus vaccine)
Trial: 8578808
Drug: RRV vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRV vaccines
Trial: 17293228
Drug: Granulocyte-macrophage colony
RxNorm normalized name: Recombinant human granulocyte-macrophage colony stimulating factor
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granulocyte-macrophage colony stimulating factor (GM-CSF) 250 microg/m2, subcutaneous injection, 3 times a week
Trial: 16573802
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg twice daily plus Aspirin 325 mg once daily (E40 b.d. + A325)
Trial: 16573802
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg twice daily plus Rofecoxib 25 mg once daily (E40 b.d. + R25)
Trial: 16573802
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg twice daily (E40 b.d.)
Trial: 16573802
Drug: Rofecoxib 25
RxNorm normalized name: rofecoxib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 25 mg once daily (R25)
Trial: 16573802
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Esomeprazole 40 mg b.d. and Rofecoxib 25 mg once daily)
Trial: 12796713
Drug: 6.72% sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.72% sodium lactate infusion at a rate of 50 micro mol. kg‐1. min‐1 for 20 minutes, then reduced to 30 micro mol. kg‐1. min‐1
Trial: 12796713
Drug: 1.4% sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.4% sodium bicarbonate infusion
Trial: 10352333
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg aspirin daily for 7 days
Trial: 1742818
Drug: Ketamine 2
RxNorm normalized name: esketamine 28 mg nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 2 mg.kg‐1 and midazolam 0.2 mg.kg‐1 (Group I)
Trial: 1742818
Drug: Ketamine 2
RxNorm normalized name: esketamine 28 mg nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 2 mg.kg‐1 and midazolam 0.4 mg.kg‐1 (Group II)
Trial: 1742818
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of midazolam (0.4 mg.kg‐1)
Trial: 26237453
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment plus SRP
Trial: 20299535
Drug: Wake up
RxNorm normalized name: Wake Ups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wake up and breathe protocol (interrupts and reduces sedative exposure)
Trial: 20299535
Drug: Sedation per
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedation per usual care plus daily SBTs (control)
Trial: 16080072
Drug: Tigecycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tigecycline (100 mg followed by 50 mg intravenously twice daily)
Trial: 16080072
Drug: Vancomycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (1 g intravenously twice daily) plus Aztreonam (2 g intravenously twice daily)
Trial: 1922662
Drug: Alternate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate treatment with Prednisone (Polfa) and Decaris (Richter)
Trial: 23099809
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy with 5‐FU/LEV
Trial: 17653259
Drug: Prosaptide (PRO)
RxNorm normalized name: Climara Pro
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prosaptide (PRO) 8 mg/d
Trial: 17653259
Drug: Prosaptide (PRO)
RxNorm normalized name: Climara Pro
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prosaptide (PRO) 16 mg/d
Trial: 15277146
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g c9,t11 CLA/d
Trial: 11023084
Drug: Pyrvinium pamoate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrvinium pamoate, 5 mg/kg/day for 3 days
Trial: 1337525
Drug: Lomefloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomefloxacin (400 mg orally once daily)
Trial: 1337525
Drug: TMP/SMX (160/800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMP/SMX (160/800 mg orally twice daily)
Trial: 22241602
Drug: Granisetron 40
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron 40 μg/kg
Trial: 22241602
Drug: Granisetron 10
RxNorm normalized name: GRANISETRON 10MG/0.4ML INJ,SYRINGE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 10 μg/kg
Trial: 22241602
Drug: Granisetron 10
RxNorm normalized name: GRANISETRON 10MG/0.4ML INJ,SYRINGE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 10 μg/kg and 40 μg/kg
Trial: 15386762
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy for women with recently diagnosed primary breast cancer
Trial: 9527733
Drug: Thiopentone induction
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopentone induction and isoflurane maintenance plus ondansetron 5 mg x m(‐2) i.v.
Trial: 9527733
Drug: Propofol induction
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol induction and maintenance plus lignocaine 2 mg x kg(‐1) i.v.
Trial: 7608323
Drug: Rivastatin 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastatin 300 micrograms once daily
Trial: 194679
Drug: L phenylalanine
RxNorm normalized name: UNDECYLENOYL PHENYLALANINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L phenylalanine mustard (L PAM)
Trial: 194679
Drug: L PAM
RxNorm normalized name: OXANTEL PAMOATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L PAM
Trial: 22154118
Drug: FEC-DH (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC-DH (4 cycles of FEC followed by 4 cycles of trastuzumab and 4 cycles of docetaxel 75 mg/m(2))
Trial: 16305563
Drug: Misoprostol 400
RxNorm normalized name: Misoprostol 400 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol 400 mcg/1.5 mL gel solution
Trial: 12819295
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment with epoetin beta (NeoRecormon) administered subcutaneously aiming for a target Hb level of 13‐15 g/dl.
Trial: 12819295
Drug: Late treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late treatment with epoetin beta (NeoRecormon) administered subcutaneously starting once Hb level declines to below 10.5 g/dl (target Hb level 10.5‐11.5 g/dl).
Trial: 1863026
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of bumetanide (12 mg over 12 hours)
Trial: 1863026
Drug: Bolus therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus therapy of bumetanide (two 6 mg doses separated by 6 hours)
Trial: 1863026
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of bumetanide
Trial: 1863026
Drug: Bolus therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus therapy of bumetanide
Trial: 6756931
Drug: Terbutaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline infusion during placebo